[Skip to Content]
[Skip to Content Landing]
Invited Commentary
July 2015

Risks of Different Testosterone Preparations: Too Much, Too Little, Just Right

Author Affiliations
  • 1Department of Medicine, University of Colorado School of Medicine, Aurora
  • 2Research Service, Denver Veterans Affairs Medical Center, Denver, Colorado
JAMA Intern Med. 2015;175(7):1197-1198. doi:10.1001/jamainternmed.2015.1580

There is a developing story that the increased use of testosterone therapy without a diagnosis of hypogonadism is associated with an elevated cardiovascular risk for some patients. In this issue of JAMA Internal Medicine, Layton and coauthors1 deepen our knowledge with their analysis of 3 large databases (Truven MarketScan and Medicare cohorts from the United States and the Clinical Practice Research Datalink cohort from the United Kingdom) to ask whether they could detect a difference in cardiovascular or cerebrovascular events and mortality in patients newly prescribed testosterone therapy in the form of injectable testosterone compared with testosterone gels or patches.

×